Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
17.27
-0.32 (-1.82%)
At close: Dec 26, 2025, 4:00 PM EST
18.00
+0.73 (4.23%)
After-hours: Dec 26, 2025, 7:32 PM EST
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Atara Biotherapeutics stock have an average target of 25, which predicts a 44.76% increase from the current stock price of 17.27.
Price Target: $25 (+44.76%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 → $25 | Strong Buy | Maintains | $17 → $25 | +44.76% | Dec 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | -1.56% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | -1.56% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
123.67M
from 128.94M
Decreased by -4.09%
Revenue Next Year
59.10M
from 123.67M
Decreased by -52.21%
EPS This Year
2.14
from -11.41
EPS Next Year
0.08
from 2.14
Decreased by -96.42%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 130.2M | 76.7M | ||||
| Avg | 123.7M | 59.1M | ||||
| Low | 116.8M | 43.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.0% | -38.0% | ||||
| Avg | -4.1% | -52.2% | ||||
| Low | -9.4% | -65.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.59 | 0.91 | ||||
| Avg | 2.14 | 0.08 | ||||
| Low | 1.69 | -0.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -57.3% | ||||
| Avg | - | -96.4% | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.